Perspective Therapeutics, Inc. - CATX STOCK NEWS

Perspective Therapeutics announced initial results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors at the 2024 NANETS Symposium. The trial showed favorable safety profile with no dose-limiting toxicities at tested doses (2.5 and 5.0 mCi). Eight of nine patients achieved durable disease control, with six showing measurable tumor volume reduction. One patient achieved confirmed response per RECIST v1.1. The Safety Monitoring Committee recommended proceeding with dose escalation and expanding patient enrollment at 5.0 mCi. The company plans to consult with FDA for Cohort 3 initiation.

Perspective Therapeutics (NYSE AMERICAN: CATX) announced the upcoming presentation of initial results from their Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 NANETS Multidisciplinary NET Medical Symposium. The presentation, titled 'Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 expressing neuroendocrine tumors,' will be delivered by Dr. Richard L. Wahl on November 22, 2024. The company will host a conference call on November 21 to discuss the data, featuring Dr. Wahl and including a Q&A session.

Perspective Therapeutics (NYSE AMERICAN: CATX) reported Q3 2024 financial results and business updates. The company has $267.8 million in cash and investments, expected to fund operations into mid-2026. Key developments include advancing [212Pb]VMT01 trials in melanoma patients and [212Pb]VMT-α-NET in neuroendocrine tumors. The company started shipping from a second manufacturing facility in Somerset, New Jersey, and purchased additional facilities in Houston, Chicago, and Los Angeles. Q3 2024 showed a net loss of $15.1 million ($0.21 per share), with research and development expenses at $12.0 million and general administrative expenses at $7.0 million.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, will report its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the market closes. The press release will be available in the newsroom section of the Company's website.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focusing on cancer treatments, has announced its participation in four major investor conferences this November. The company will attend the Truist Securities BioPharma Symposium (Nov 7) in New York for one-on-one meetings, the UBS Global Healthcare Conference (Nov 13) in California featuring a fireside chat, the Stifel Healthcare Conference (Nov 18) in New York with a fireside chat, and the Jefferies London Healthcare Conference (Nov 19-21) for one-on-one meetings. Webcasts of applicable events will be available live and archived for 90 days on the company's investor website.

Perspective Therapeutics (NYSE AMERICAN: CATX) presented six updates on its radiopharmaceutical programs at the 37th Annual EANM Congress in Hamburg. The presentations included preclinical studies and first-in-human imaging data for [212Pb]Pb-PSV359, showing strong tumor uptake and anti-tumor efficacy. Updates on [212Pb]Pb-VMT-α-NET revealed promising interim clinical results in NET patients, with confirmed tumor responses in six of ten GEP-NETs patients. The presentations also covered biodistribution studies, chelator evaluations, and development of imaging surrogates for therapeutic radiopharmaceuticals.

Perspective Therapeutics (NYSE AMERICAN: CATX) has begun shipping investigational products from its new radiopharmaceutical manufacturing facility in Somerset, New Jersey. This state-of-the-art facility is now operational, supporting VMT-α-NET clinical studies alongside the existing Coralville, Iowa facility. With three cGMP-compliant manufacturing suites, it's expected to meet future clinical trial and commercial demands in the Northeastern U.S.

The Somerset facility, acquired from Lantheus Holdings in March 2024, previously produced FDA-approved Azedra for rare adrenal gland tumors. This milestone comes just seven months after acquisition, accelerating Perspective's efforts in delivering investigational products and potential new radiopharmaceutical therapies. The company aims to replicate this approach, adding strategic sites to enhance its network supporting key treatment hubs across the U.S.

Perspective Therapeutics (NYSE AMERICAN: CATX) presented initial results from its Phase 1/2a study of [212Pb]VMT01, a MC1R-targeted radiopharmaceutical therapy for melanoma, at the 21st International Congress of the Society for Melanoma Research. Key findings include:

1. Safety: No dose-limiting toxicities observed at 3.0 and 5.0 mCi doses.

2. Efficacy: Prolonged progression-free survival and tumor response in heavily pretreated patients at the 3.0 mCi dose.

3. The trial is progressing with a lower 1.5 mCi dose to optimize immunostimulatory activities, both as monotherapy and in combination with nivolumab.

4. The Safety Monitoring Committee recommended exploring the 1.5 mCi dose level as a single agent and in combination with nivolumab.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, announced that initial results from its Phase 1/2a study of [212Pb]VMT01 have been selected for a poster presentation at the 21st International Congress of the Society for Melanoma Research (SMR). The event will be held on October 10-13, 2024, in New Orleans, Louisiana.

The study, titled “First in Human Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Melanoma (MM),” marks the company's first scientific presentation of clinical data from a company-sponsored study. CEO Thijs Spoor highlighted the ongoing exploration of the optimal dose of [212Pb]VMT01 in metastatic melanoma, both as a single agent and in combination with nivolumab.

Perspective will host a conference call on October 11, 2024, at 9am ET to review the data presented at SMR. Details will be available on the Events page of the company's website.